{"entity":{"id":"nct06868199","kind":"trial","name":"A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours","aka":[],"tldr":"A phase 1/2 trial of Toripalimab in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.","summary":"A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06868199 by LaNova Medicines Limited, with 87 participants planned, started 2025-05-06 and due to reach its primary completion in 2027-08-01. Interventions recorded: LM-168 and Toripalimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06868199","url":"https://clinicaltrials.gov/study/NCT06868199"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["toripalimab"],"companies":["lanova-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06868199","phase":"1/2","setting":"A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours","sponsor":"LaNova Medicines Limited","participation":[{"nct":"NCT06868199","source":"https://clinicaltrials.gov/study/NCT06868199","fetchedAt":"2026-10-07T16:55:12.940Z","studySha256":"c554170dd55d06c2f1bda59ce874ff0df4d89399ab2595efcdf5f42755843c0c","overallStatus":"RECRUITING","lastUpdatePosted":"2025-09-12","leadSponsor":"LaNova Medicines Limited","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":87,"enrolmentType":"ESTIMATED","siteCount":6,"recruitingSiteCount":5,"countries":["Australia","China"]}],"started":"2025-05-06","startedType":"actual","enrolled":87,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06868199/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/"}]}}